HMGB1 is a Potential and Challenging Therapeutic Target for Parkinson's Disease

Cell Mol Neurobiol. 2023 Jan;43(1):47-58. doi: 10.1007/s10571-021-01170-8. Epub 2021 Nov 19.


Parkinson's disease (PD) is one of the most common degenerative diseases of the human nervous system and has a wide range of serious impacts on human health and quality of life. Recently, research targeting high mobility group box 1 (HMGB1) in PD has emerged, and a variety of laboratory methods for inhibiting HMGB1 have achieved good results to a certain extent. However, given that HMGB1 undergoes a variety of intracellular modifications and three different forms of extracellular redox, the possible roles of these forms in PD are likely to be different. General inhibition of all forms of HMGB1 is obviously not ideal and has become one of the biggest obstacles in the clinical application of targeting HMGB1. In this review, pure mechanistic research of HMGB1 and in vivo research targeting HMGB1 were combined, the effects of HMGB1 on neurons and immune cell responses in PD are discussed in detail, and the problems that need to be focused on in the future are addressed.

Keywords: Autophagy; HMGB1; Microglia; Neuroinflammation; Parkinson’s disease; T cell.

Publication types

  • Review

MeSH terms

  • HMGB1 Protein*
  • Humans
  • Microglia
  • Neurons
  • Parkinson Disease* / drug therapy
  • Quality of Life


  • HMGB1 Protein